Cerebral blood flow in sickle cell cerebrovascular disease.
Cerebral blood flow (CBF) has been studied by the xenon-133 (133Xe) inhalation method in 16 children with suspected sickle cell cerebrovascular disease. Abnormalities consisting of decreases in total, hemispheral, or regional CBF were found in 17 of 26 studies. Eleven studies performed immediately after stroke, transient ischemic attack, or depression of state of alertness showed abnormalities. In addition to confirming regional cerebrovascular insufficiency in children with stroke due to major cerebral artery occlusion, the method detected diffuse decrease in CBF in children with stupor, coma, and seizures who had normal angiographic findings. In contrast, six of seven studies obtained after exchange transfusion or during maintenance on hypertransfusion therapy showed normal findings. The difference between results in patients with acute neurologic disturbances and those receiving transfusion therapy was statistically significant (P less than .005). The data indicate that the 133Xe method reliably demonstrates cerebrovascular impairment in sickle cell disease. They also suggest that CBF changes in patients with sickle cell disease can be reversed by exchange transfusion and by hypertransfusion therapy. The 133Xe CBF method may be useful for following up children with sickle cell disease who are at high risk for recurrent stroke.
D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000000981:diagnostic imaging / Q000628:therapy; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging*; D002648:Child; D002675:Child, Preschool; D003128:Coma / Q000000981:diagnostic imaging; D005078:Exchange Transfusion, Whole Blood; D006801:Humans; D007223:Infant; D002546:Ischemic Attack, Transient / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D012039:Regional Blood Flow; D012640:Seizures / Q000000981:diagnostic imaging; D014980:Xenon Radioisotopes
D014980:Xenon Radioisotopes